

Figure S1. Phage ELISA against SARS-2 RBD with phages from each of the 3rd round (a) and 4th round (b) of the panning using the KFab-I library. The red dot lines indicate the cut off for selecting positive clones. Abbreviations: ELISA, enzyme-linked immunosorbent assay; A450 nm, Absorbance at 450 nm.



Figure S2. Monoclonal ELISA of 10 Fab phage clones against SARS-2 RBD and its variants. The numbers in each variants indicate positions on the RBD that mutations occurred. Abbreviations: N, Asparagine; D, Aspartate; W, Tryptophan; Y, Tyrosine; V, Valine; R, Arginine; F, Phenylalanine.



Figure S3. SDS-PAGE analysis of 10 human anti-SARS-2 RBD Fabs purified from periplasmic extracts of *E. coli*. + and – indicate with and without the reducing reagent (β -mercaptoethanol), respectively. kDa, kilodalton. The bars under kDa mark the positions of the molecular mass markers.



Figure S4. Flow cytometry analysis of blocking effect of human anti-SARS-2 RBD Fabs between SARS-CoV-2 RBD-mFc and ACE2-overexpressed cells. NC, a negative control, is cells only (grey line); PC, a positive control, is cells treated with SARS-CoV-2 RBD-mFc (red line); Blue and green lines indicate cells treated with mixture of SARS-CoV-2 RBD-mFc and anti-SARS-2 RBD Fabs of 50 µg/mL and 100 µg/mL, respectively.



Figure S5. ELISA of 10 human anti-SARS-2 RBD Fabs against S1 proteins from SARS-CoV-2 (green), SARS-CoV (blue), and MERS-CoV (red).



Figure S6. SDS-PAGE analysis of five human anti-SARS-2 RBD IgGs produced in HEK293 cells. β -MER (+) and β -MER (-) indicate with and without the reducing reagent (β -mercaptoethanol), respectively. kDa, kilodalton. The bars under kDa mark the positions of the molecular mass markers.



Figure S7. Determination of melting temperatures (T_{ms}) of five human anti-SARS-2 RBD IgGs using a PTS assay. T_{m1} and T_{m2} are the first and second apparent melting temperatures determined by a differential scanning fluorimetry (DSF), respectively.



Figure S8. Determination of the melting temperatures (T_{ms}) of five human anti-SARS-2 RBD Fabs using a PTS assay. T_m1 and T_m2 are the first and second apparent melting temperatures determined by a differential scanning fluorimetry (DSF), respectively.



PE anti-mouse IgG2a

Figure S9. Flow cytometry analysis of blocking effect of human anti-SARS-2 RBD IgGs between SARS-CoV-2 RBD-mFc and ACE2-overexpressed cells. NC, a negative control, is cells only (grey line); PC, a positive control, is cells treated with SARS-CoV-2 RBD-mFc (red line); Blue line indicates cells treated with mixture of SARS-CoV-2 RBD-mFc and anti-SARS-2 RBD IgGs of 50 µg/mL.



Figure S10. Neutralization assay of three human anti-SARS-2 RBD IgGs (C12, F7, and H1) on authentic SARS-CoV-2. Data presented as mean \pm SE (SEM). Abbreviation: RLU, Relative luminescence units; *IC*₅₀A, *IC*₅₀ determined by authentic SARS-CoV-2 virus. RLU was normalized by subtracting values from the blank controls corresponding to each data points.



Figure S11. Affinity determination of human anti-SARS-2 RBD IgGs using a BLI (Octet). Black and red lines indicate data points measured from different concentrations and corresponding fitted curves, respectively. Abbreviation: *K*_{on} and *K*_{off}, association and dissociation constants, respectively; *K*_D, equilibrium dissociation constant.